Enterobacter aerogenes: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
One possible identification code generated by testing ''E. aerogenes'' using an API strip is 5 305 773. | One possible identification code generated by testing ''E. aerogenes'' using an API strip is 5 305 773. | ||
==Treatment Regimen== | |||
:* '''Enterobacter species including <i>E. aerogenes</i> and <i>E. cloacae</i>'''<ref>{{Cite journal| issn = 0893-8512| volume = 10| issue = 2| pages = 220–241| last1 = Sanders| first1 = W. E.| last2 = Sanders| first2 = C. C.| title = Enterobacter spp.: pathogens poised to flourish at the turn of the century| journal = Clinical Microbiology Reviews| date = 1997-04| pmid = 9105752| pmc = PMC172917}}</ref><ref>{{Cite journal| doi = 10.1128/CMR.00036-08| issn = 1098-6618| volume = 22| issue = 1| pages = 161–182| last = Jacoby| first = George A.| title = AmpC beta-lactamases| journal = Clinical Microbiology Reviews| date = 2009-01| pmid = 19136439| pmc = PMC2620637}}</ref><ref>{{Cite journal| doi = 10.1128/CMR.18.4.657-686.2005| issn = 0893-8512| volume = 18| issue = 4| pages = 657–686| last1 = Paterson| first1 = David L.| last2 = Bonomo| first2 = Robert A.| title = Extended-spectrum beta-lactamases: a clinical update| journal = Clinical Microbiology Reviews| date = 2005-10| pmid = 16223952| pmc = PMC1265908}}</ref><ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref><ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref> | |||
::* 1. '''Empiric antimicrobial therapy pending <i>in vitro</i> susceptibility''' | |||
:::* 1.1 '''Non–life-threatening infections or MDR-GNB prevalence < 20%''' | |||
::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 g IV q6h {{withorwithout}} [[Aminoglycosides]] | |||
::::* Alternative regimen: [[Ciprofloxacin]] 400 mg IV q8–12h | |||
:::* 1.2 '''Life-threatening infections or MDR-GNB prevalence > 20%''' | |||
::::* Preferred regimen: [[Meropenem]] 0.5–1 g IV q8h | |||
::::* Alternative regimen (1): [[Colistin]] {{and}} [[Meropenem]] 0.5–1 g IV q8h | |||
::::* Alternative regimen (2): [[Colistin]] {{and}} [[Imipenem]] 500 mg IV q6h | |||
::::* Alternative regimen (3): [[Colistin]] {{and}} [[Doripenem]] 500 mg IV q8h | |||
::::* Alternative regimen (4): [[Colistin]] {{and}} [[Ertapenem]] 1 g IV q24h | |||
::::* Alternative regimen (5): [[Colistin]] {{and}} [[Fosfomycin]] 6 g IV q6h | |||
::* 2. '''<i>In vitro</i> susceptibility available''' | |||
:::* 2.1 '''Susceptible to all tested agents''' | |||
::::* Preferred regimen: [[Piperacillin-Tazobactam]] 3.375 g IV q6h | |||
::::* Alternative regimen (1): [[Ciprofloxacin]] 400 mg IV q8–12h | |||
::::* Alternative regimen (2): [[Cefepime]] 2 g IV q8h (if MIC ≤ 1 μg/mL) | |||
:::* 2.2 '''Extended spectrum beta-lactamase (ESBL)-producing Enterobacter spp.''' | |||
::::* Preferred regimen: [[Meropenem]] 0.5–1 g IV q8h | |||
::::* Alternative regimen (1): [[Imipenem]] 500 mg IV q6h | |||
::::* Alternative regimen (2): [[Doripenem]] 500 mg IV q8h | |||
::::* Alternative regimen (3): [[Ertapenem]] 1 g IV q24h | |||
::::* Alternative regimen (4): [[Cefepime]] 2 g IV q8h (if MIC ≤ 1 μg/mL) | |||
:::* 2.3 '''Resistant to all tested agents''' | |||
::::* Preferred regimen: [[Colistin]] {{and}} [[Meropenem]] 0.5–1 g IV q8h | |||
::::* Alternative regimen (1): [[Colistin]] {{and}} [[Imipenem]] 500 mg IV q6h | |||
::::* Alternative regimen (2): [[Colistin]] {{and}} [[Doripenem]] 500 mg IV q8h | |||
::::* Alternative regimen (3): [[Colistin]] {{and}} [[Ertapenem]] 1 g IV q24h | |||
::::* Alternative regimen (4): [[Colistin]] {{and}} [[Minocycline]] 100 mg IV q12h | |||
[[Category: Enterobacteria]] | [[Category: Enterobacteria]] | ||
[[Category: Gram negative bacteria]] | [[Category: Gram negative bacteria]] | ||
[[Category: Infectious Disease Project]] | |||
{{Proteobacteria-stub}} | {{Proteobacteria-stub}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 20:38, 7 August 2015
| Enterobacter aerogenes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||
| ||||||||||||
| Binomial name | ||||||||||||
| Enterobacter aerogenes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Enterobacter aerogenes is a Gram-negative, oxidase negative, catalase positive, rod-shaped bacterium.
E. aerogenes is a nosocomial pathogen that causes opportunistic skin and tissue infections. Some strains can become very treatment resistant, a result of their colonization within hospital environments.
Most of the infections caused by E. aerogenes result from specific antibiotic treatments, venous catheter insertions, and/or surgical procedures. E. aerogenes is generally found in the human intestinal tract and does not generally cause disease in healthy individuals. It has been found to live in various wastes, hygenic chemicals, and soil. The bacterium also has some commercial significance - the hydrogen gas produced during fermentation has been experimented with in the production of molasses.
One possible identification code generated by testing E. aerogenes using an API strip is 5 305 773.
Treatment Regimen
-
- 1. Empiric antimicrobial therapy pending in vitro susceptibility
- 1.1 Non–life-threatening infections or MDR-GNB prevalence < 20%
- Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h ± Aminoglycosides
- Alternative regimen: Ciprofloxacin 400 mg IV q8–12h
- 1.2 Life-threatening infections or MDR-GNB prevalence > 20%
- Preferred regimen: Meropenem 0.5–1 g IV q8h
- Alternative regimen (1): Colistin AND Meropenem 0.5–1 g IV q8h
- Alternative regimen (2): Colistin AND Imipenem 500 mg IV q6h
- Alternative regimen (3): Colistin AND Doripenem 500 mg IV q8h
- Alternative regimen (4): Colistin AND Ertapenem 1 g IV q24h
- Alternative regimen (5): Colistin AND Fosfomycin 6 g IV q6h
- 2. In vitro susceptibility available
- 2.1 Susceptible to all tested agents
- Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h
- Alternative regimen (1): Ciprofloxacin 400 mg IV q8–12h
- Alternative regimen (2): Cefepime 2 g IV q8h (if MIC ≤ 1 μg/mL)
- 2.2 Extended spectrum beta-lactamase (ESBL)-producing Enterobacter spp.
- 2.3 Resistant to all tested agents
- Preferred regimen: Colistin AND Meropenem 0.5–1 g IV q8h
- Alternative regimen (1): Colistin AND Imipenem 500 mg IV q6h
- Alternative regimen (2): Colistin AND Doripenem 500 mg IV q8h
- Alternative regimen (3): Colistin AND Ertapenem 1 g IV q24h
- Alternative regimen (4): Colistin AND Minocycline 100 mg IV q12h
Template:Proteobacteria-stub Template:WikiDoc Sources
- ↑ Sanders, W. E.; Sanders, C. C. (1997-04). "Enterobacter spp.: pathogens poised to flourish at the turn of the century". Clinical Microbiology Reviews. 10 (2): 220–241. ISSN 0893-8512. PMC 172917. PMID 9105752. Check date values in:
|date=(help) - ↑ Jacoby, George A. (2009-01). "AmpC beta-lactamases". Clinical Microbiology Reviews. 22 (1): 161–182. doi:10.1128/CMR.00036-08. ISSN 1098-6618. PMC 2620637. PMID 19136439. Check date values in:
|date=(help) - ↑ Paterson, David L.; Bonomo, Robert A. (2005-10). "Extended-spectrum beta-lactamases: a clinical update". Clinical Microbiology Reviews. 18 (4): 657–686. doi:10.1128/CMR.18.4.657-686.2005. ISSN 0893-8512. PMC 1265908. PMID 16223952. Check date values in:
|date=(help) - ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.